IBRX PE Ratio & Valuation,Is IBRX Overvalued

IBRX Relative Valuation

IBRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IBRX is overvalued; if below, it's undervalued.

Historical Valuation

Immunitybio Inc (IBRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 13.58 is considered Undervalued compared with the five-year average of -7.79. The fair price of Immunitybio Inc (IBRX) is between 11.86 to 12.89 according to relative valuation methord. Compared to the current price of 2.21 USD , Immunitybio Inc is Undervalued By 81.36%.

Relative Value

Fair Zone

11.86-12.89

Current Price：2.21

81.36%

Undervalued

-6.21

0.00

EV/EBITDA

Immunitybio Inc. (IBRX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-11.74

EV/EBIT

Immunitybio Inc. (IBRX) has a current EV/EBIT of -11.74. The 5-year average EV/EBIT is -10.77. The thresholds are as follows: Strongly Undervalued below -24.65, Undervalued between -24.65 and -17.71, Fairly Valued between -3.83 and -17.71, Overvalued between -3.83 and 3.11, and Strongly Overvalued above 3.11. The current Forward EV/EBIT of -11.74 falls within the Historic Trend Line -Fairly Valued range.

13.58

Immunitybio Inc. (IBRX) has a current PS of 13.58. The 5-year average PS is 9270.32. The thresholds are as follows: Strongly Undervalued below -25543.77, Undervalued between -25543.77 and -8136.72, Fairly Valued between 26677.37 and -8136.72, Overvalued between 26677.37 and 44084.42, and Strongly Overvalued above 44084.42. The current Forward PS of 13.58 falls within the Historic Trend Line -Fairly Valued range.

-11.71

P/OCF

Immunitybio Inc. (IBRX) has a current P/OCF of -11.71. The 5-year average P/OCF is -4.28. The thresholds are as follows: Strongly Undervalued below -12.71, Undervalued between -12.71 and -8.50, Fairly Valued between -0.07 and -8.50, Overvalued between -0.07 and 4.15, and Strongly Overvalued above 4.15. The current Forward P/OCF of -11.71 falls within the Undervalued range.

-11.07

P/FCF

Immunitybio Inc. (IBRX) has a current P/FCF of -11.07. The 5-year average P/FCF is -10.00. The thresholds are as follows: Strongly Undervalued below -25.62, Undervalued between -25.62 and -17.81, Fairly Valued between -2.19 and -17.81, Overvalued between -2.19 and 5.62, and Strongly Overvalued above 5.62. The current Forward P/FCF of -11.07 falls within the Historic Trend Line -Fairly Valued range.

Immunitybio Inc (IBRX) has a current Price-to-Book (P/B) ratio of -4.43. Compared to its 3-year average P/B ratio of -4.03 , the current P/B ratio is approximately 9.82% higher. Relative to its 5-year average P/B ratio of -9.01, the current P/B ratio is about -50.86% higher. Immunitybio Inc (IBRX) has a Forward Free Cash Flow (FCF) yield of approximately -13.97%. Compared to its 3-year average FCF yield of -21.43%, the current FCF yield is approximately -34.80% lower. Relative to its 5-year average FCF yield of -18.13% , the current FCF yield is about -22.95% lower.

-4.14

P/B

Median3y

-4.03

Median5y

-9.01

-13.97

FCF Yield

Median3y

-21.43

Median5y

-18.13

Competitors Valuation Multiple

The average P/S ratio for IBRX's competitors is 2.52, providing a benchmark for relative valuation. Immunitybio Inc Corp (IBRX) exhibits a P/S ratio of , which is -100% above the industry average. Given its robust revenue growth of 425.07%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of IBRX decreased by 7.81% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 6.11M to 32.06M.

The secondary factor is the Margin Expansion, contributed -85.06%to the performance.

Overall, the performance of IBRX in the past 1 year is driven by Revenue Growth. Which is more sustainable.

425.07%

6.11M → 32.06M

Revenue Growth

-85.06%

-1.40K → -209.83

Margin Expansion

-347.82%

2.14 → -5.31

P/E Change

-7.81%

2.56 → 2.36

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Immunitybio Inc (IBRX) currently overvalued or undervalued?

What is Immunitybio Inc (IBRX) fair value?

IBRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Immunitybio Inc (IBRX) is between 11.86 to 12.89 according to relative valuation methord.

How does IBRX's valuation metrics compare to the industry average?

The average P/S ratio for IBRX's competitors is 2.52, providing a benchmark for relative valuation. Immunitybio Inc Corp (IBRX) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 425.07%, this premium appears sustainable.

What is the current P/B ratio for Immunitybio Inc (IBRX) as of Dec 16 2025?

As of Dec 16 2025, Immunitybio Inc (IBRX) has a P/B ratio of -4.43. This indicates that the market values IBRX at -4.43 times its book value.

What is the current FCF Yield for Immunitybio Inc (IBRX) as of Dec 16 2025?

As of Dec 16 2025, Immunitybio Inc (IBRX) has a FCF Yield of -13.97%. This means that for every dollar of Immunitybio Inc’s market capitalization, the company generates -13.97 cents in free cash flow.

What is the current Forward P/E ratio for Immunitybio Inc (IBRX) as of Dec 16 2025?

As of Dec 16 2025, Immunitybio Inc (IBRX) has a Forward P/E ratio of -6.64. This means the market is willing to pay $-6.64 for every dollar of Immunitybio Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Immunitybio Inc (IBRX) as of Dec 16 2025?

As of Dec 16 2025, Immunitybio Inc (IBRX) has a Forward P/S ratio of 13.58. This means the market is valuing IBRX at $13.58 for every dollar of expected revenue over the next 12 months.

IBRX Valuation